0001387131-20-005871.txt : 20200622
0001387131-20-005871.hdr.sgml : 20200622
20200622172913
ACCESSION NUMBER: 0001387131-20-005871
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200622
FILED AS OF DATE: 20200622
DATE AS OF CHANGE: 20200622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36033
FILM NUMBER: 20979719
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Theravance Biopharma, Inc.
CENTRAL INDEX KEY: 0001583107
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET
CITY: GEORGE TOWN, GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
BUSINESS PHONE: 650-808-6000
MAIL ADDRESS:
STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET
CITY: GEORGE TOWN, GRAND CAYMAN
STATE: E9
ZIP: KY1-1104
4
1
tbph-form4_062220.xml
OWNERSHIP DOCUMENT
X0306
4
2020-06-22
0
0001583107
Theravance Biopharma, Inc.
TBPH
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
0
0
1
0
Exchangeable Note
29.0660
2020-06-22
4
S
0
280336000
D
Ordinary Shares
9644792
0
I
See Footnote
On June 22, 2020, GSK Finance No.3 plc ("GSK Finance"), a wholly owned indirect subsidiary of GlaxoSmithKline plc ("GSK"), issued $280,336,000 of its senior notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma"). The Ordinary Shares are held directly by GSK Finance.
The Notes are guaranteed by GSK and exchangeable at the option of noteholders on any business day on or after September 1, 2020 for up to 9,644,792 Ordinary Shares at an initial exchange rate of 34.4044 Ordinary Shares per $1,000 principal amount of Notes, which is equivalent to an initial exchange price of approximately $29.0660. Under certain circumstances, GSK Finance may deliver cash in lieu of Ordinary Shares or a combination of Ordinary Shares and cash. The sale of the Notes resulted in $304,164,560 of gross proceeds.
/s/ Victoria Whyte
2020-06-22